Hadas Reuveni

This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Novotyr Therapeutics Ltd., Tyrnovo Ltd.. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hadas Reuveni. Retrieved from https://idiyas.com/inventor/hadas-reuveni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 6)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Aminadav, IL (1999)
Yehuda, IL (2005)
D.N. Harei Yehuda, IL (2010)
Har Adar, IL (2011 - 2021)

Company Filing History:

7 out of 915

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

2 out of 2

Novotyr Therapeutics Ltd.

Develogen Israel Ltd.

patents

5. 1 out of 182

Hadasit Medical Research Services and Development Ltd.

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12201592 - Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer (2025-01-21),

2. 10912745 - Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer (2021-02-09),

3. 10188659 - IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases (2019-01-29),

4. 9873724 - Pro-angiogenic peptides and peptide conjugates (2018-01-23),

5. 9770454 - IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases (2017-09-26),

6. 9073880 - 2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer (2015-07-07),

7. 8637575 - Modulators of protein kinase signaling (2014-01-28),

8. 8575307 - Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes (2013-11-05),

9. 8058309 - Protein kinase modulators and therapeutic uses thereof (2011-11-15),

10. 7683031 - [object Object] (2010-03-23),

11. 6949565 - Protein kinase inhibitors (2005-09-27),

12. 5990277 - Semipeptoid farnesyl protein transferase inhibitors and analogs thereof (1999-11-23),

Title: Hadas Reuveni: Innovator in Cancer Treatment

Introduction

Hadas Reuveni is a prominent inventor based in Har Adar, Israel. She has made significant contributions to the field of cancer treatment, holding a total of 12 patents. Her innovative work focuses on developing therapies that address the challenges of tumor resistance to various cancer treatments.

Latest Patents

One of Hadas Reuveni's latest patents involves the use of combinations of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3) dual modulators alongside anti-cancer agents. This treatment aims to combat cancer by targeting tumors that have developed resistance to EGFR inhibitors, EGFR antibodies, mTOR inhibitors, MEK inhibitors, mutated B-Raf inhibitors, and chemotherapeutic agents. The patent also outlines methods to prevent acquired resistance and tumor recurrence after treatment cessation. Additionally, her work includes combination therapies that utilize IRS and Stat3 dual modulators in conjunction with immunotherapy agents to enhance tumor sensitivity to immunotherapy.

Career Highlights

Throughout her career, Hadas Reuveni has worked with notable organizations, including Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Novotyr Therapeutics Ltd. Her research has significantly advanced the understanding and treatment of cancer.

Collaborations

Hadas has collaborated with esteemed colleagues such as Alexander Levitzki and Shmuel A Ben-Sasson, contributing to the development of innovative cancer therapies.

Conclusion

Hadas Reuveni's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. Her patents and collaborations highlight her commitment to advancing therapeutic options for patients facing challenging cancers.

Profile summary based on public USPTO records.